INDEMNIFICATION AGREEMENTIndemnification Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
This Indemnification Agreement (this “Agreement”) is entered into as of __________ by and between Neurogene Inc., a Delaware corporation (the “Company”), and __________ (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.
SEPARATION AGREEMENT AND RELEASESeparation Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • Washington
This Separation Agreement and Release (this “Agreement”) is made and entered into by and between Donna Cochener (“Employee”) and Neoleukin Therapeutics, Inc. (the “Company”). The parties agree as follows:
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of December 18, 2023, is entered into by and among Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), Equiniti Trust Company, LLC, a New York limited liability trust company, as the Rights Agent, and Donna Cochener as the Lease Representative.
AMENDMENT 1 TO MASTER RESEARCH COLLABORATION AGREEMENTMaster Research Collaboration Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, a charitable body registered in Scotland under registration number SC005336, incorporated under the Universities (Scotland) Acts and having its main administrative offices at Old College, South Bridge Edinburgh, EH8 9YL (“University”); and
THIRD AMENDMENT TO THE CONSULTING AGREEMENT BETWEEN NEUROGENE INC. AND STUART COBB CONSULTING, LTD.Consulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO THE CONSULTING AGREEMENT (the “Amendment”) is entered and made effective as of April 1, 2022 (the “Amendment Effective Date”), by and between Neurogene Inc., a Delaware corporation having a place of business at 535 West 24th Street, 5th Floor, New York, NY 10011 (“Company”) and Stuart Cobb Consulting Ltd., a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX (“Consultant”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement.
FOURTH AMENDMENT TO THE CONSULTING AGREEMENT BETWEEN NEUROGENE INC. AND STUART COBB CONSULTING, LTD.Consulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO THE CONSULTING AGREEMENT (the “Amendment”) is entered and made effective as of January 1, 2023 (the “Amendment Effective Date”), by and between Neurogene Inc., a Delaware corporation having a place of business at 535 West 24th Street, 5th Floor, New York, NY 10011 (“Company”) and Stuart Cobb Consulting Ltd., a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX (“Consultant”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement.
FIRST AMENDMENT TO THE CONSULTING AGREEMENT BETWEEN NEUROGENE INC. AND STUART COBB CONSULTING, LTD.Consulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE CONSULTING AGREEMENT (the “Amendment”) is entered and made effective as of July 13, 2020 (the “Amendment Effective Date”), by and between Neurogene Inc., a Delaware corporation having a place of business at 535 West 24th Street, 5th Floor, New York, NY 10011 (“Company”) and Stuart Cobb Consulting Ltd., a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX (“Consultant”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement.
SECOND AMENDMENT TO THE CONSULTING AGREEMENT BETWEEN NEUROGENE INC. AND STUART COBB CONSULTING, LTD.Consulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO THE CONSULTING AGREEMENT (the “Amendment”) is entered and made effective as of January 1, 2020 (the “Amendment Effective Date”), by and between Neurogene Inc., a Delaware corporation having a place of business at 535 West 24th Street, 5th Floor, New York, NY 10011 (“Company”) and Stuart Cobb Consulting Ltd., a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX (“Consultant”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement.
CONSULTING AGREEMENTConsulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (the “Agreement”), made this 12th day of December 2018 is entered into by Neurogene Inc., a Delaware corporation (the “Company”) with offices at 10A 551 w21 street, New York, NY, 10011 and Stuart Cobb Consulting Ltd, a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX. (the “Consultant”).
CONSULTING AGREEMENTConsulting Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • Delaware
This Consulting Agreement (“Agreement”) is entered into as of December 17, 2023, between Neoleukin Therapeutics, Inc., a Delaware corporation, having its principal place of business at 188 East Blaine Steet, Suite 450, Seattle, WA 98102 (“Company”), and Donna Cochener, an individual whose address is [**] (“Consultant”), and shall be effective concurrently with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of July 17, 2023, by and among Company, Project North Merger Sub, Inc., a Delaware corporation, and Neurogene Inc., a Delaware corporation (such date, the “Closing Date”).
